Screener
Jazz Pharmaceuticals JAZZ Impairment of long-lived assets
Impairment of long-lived assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.
The source filing: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:10 PM EST
- Fiscal year
- FY2028
- Accession
- 0001232524-26-000013
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Non-cash interest expense | 32,542 | 21,973 | 22,378 |
| Provision for losses on accounts receivable and inventory | 19,108 | 27,758 | 11,113 |
| Deferred tax benefit | (444,971) | (208,327) | (260,217) |
| Impairment of property, plant and equipment | — | — | 61,014 |
| Other non-cash transactions | 3,103 | 17,978 | 11,343 |
| Changes in assets and liabilities: | |||
| Accounts receivable | (106,279) | (21,115) | (51,883) |
| Inventories | (86,041) | (45,542) | (13,420) |
Item 16. Form 10-K Summary
FAQ
- What is Jazz Pharmaceuticals's impairment of long-lived assets?
- Jazz Pharmaceuticals (JAZZ) reported impairment of long-lived assets of $0 in Q4 2025.
- What does impairment of long-lived assets mean?
- Impairment charges occur when the carrying value of a tangible asset exceeds its recoverable amount, requiring a write-down of the asset's value on the balance sheet. This non-cash charge reflects a loss in the asset's utility or market value. It is a critical indicator of potential operational inefficiencies or changes in the strategic value of physical assets.
Ask your AI about Jazz Pharmaceuticals's impairment of long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude